Janssen to file daratumumab in 2015 on PhII data
This article was originally published in Scrip
Executive Summary
Janssen (Johnson & Johnson) plans to submit a biologic licensing application to the US FDA and a marketing authorization application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase II data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.